RxDoctor Payments Data

Steven Delee, DO

Family Medicine · Carmel, INNPI 1407845001

Payments from drug & device makers

$9,869in general payments, 2019–2025

Across 621 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • GSK$894
  • Pfizer$694
  • AstraZeneca$593
  • Teva Pharmaceuticals USA, Inc.$468
  • plus $4K from 49 others

What the payments were for

  • Food & beverage$9,64398%
  • Education$2262%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)187$2,333
Novo Nordisk58$1,040
GSK59$894
Pfizer53$694
AstraZeneca31$593
Teva Pharmaceuticals USA, Inc.12$468
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$386
Lilly USA, LLC23$326
Amgen(2 entities)16$289
Takeda Pharmaceuticals U.S.A., Inc.13$197
Boehringer Ingelheim11$186
Sanofi-aventis U.S. LLC11$170
Ironshore Pharmaceuticals Inc.9$147
Astellas Pharma US Inc8$135
Abbott7$128
Bayer6$115
Sunovion Pharmaceuticals Inc.8$114
Johnson & Johnson8$114
Exact Sciences7$109
Kowa Pharmaceuticals America, Inc.8$107
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$101
Otsuka America Pharmaceutical, Inc.6$99
Novartis7$97
Daiichi Sankyo Inc.5$88
Biohaven Pharmaceuticals, Inc.2$86
Arbor Pharmaceuticals, Inc.1$79
Lundbeck LLC4$69
Neurocrine Biosciences, Inc.3$61
Merck3$53
E.r. Squibb & Sons, L.L.C.3$44
Shield Therapeutics Inc3$44
Eisai Inc.3$38
Esperion Therapeutics, Inc.2$34
Amarin Pharma, Inc.2$32
Mylan Specialty L.p.2$28
Nestle Healthcare Nutrition Inc.1$26
Axsome Therapeutics, Inc.1$24
Endo Pharmaceuticals Inc.2$24
Hikma Pharmaceuticals USA1$23
Aimmune Therapeutics, Inc.1$23
Nalpropion Pharmaceuticals LLC1$22
Antares Pharma, Inc.1$22
Shire North American Group Inc1$21
Tris Pharma Inc1$20
Dexcom, Inc.1$19
Sanofi Pasteur Inc.1$18
Vanda Pharmaceuticals Inc.1$17
Exeltis, USA Inc.1$16
Amneal Pharmaceuticals LLC1$15
Ardelyx, Inc.1$15
Supernus Pharmaceuticals, Inc.1$14
Avanir Pharmaceuticals, Inc.1$14
Currax Pharmaceuticals LLC1$14
Vertiflex, Inc.1$13
Biohaven Pharmaceutical Holding Company Ltd.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,869 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$142,091
Medicare patients
499
Services billed
1,844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban674$181,268
Trelegy ElliptaFluticasone/Umeclidin/Vilanter163$108,107
JardianceEmpagliflozin164$102,894
XareltoRivaroxaban297$64,686
TrulicityDulaglutide64$56,122
IngrezzaValbenazine Tosylate14$50,590
OzempicSemaglutide41$50,572
MounjaroTirzepatide43$48,152
Invega SustennaPaliperidone Palmitate17$45,790
JanuviaSitagliptin Phosphate52$37,106
EntrestoSacubitril/Valsartan77$36,837
MyrbetriqMirabegron75$35,644
FarxigaDapagliflozin Propanediol55$33,900
NuplazidPimavanserin Tartrate12$27,554
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr64$25,489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$694$181,268674 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy$894$148,681271 claims
Boehringer IngelheimJardiance, Stiolto Respimat$186$115,979189 claims
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$326$110,963373 claims
Johnson & JohnsonXarelto, Invega Sustenna$114$110,476314 claims
Neurocrine Biosciences, Inc.Ingrezza$61$50,59014 claims
Novo NordiskOzempic$1,040$50,57241 claims
AstraZenecaFarxiga, Symbicort$593$39,45171 claims
MerckJanuvia$53$37,10652 claims
NovartisEntresto$97$36,83777 claims
Astellas Pharma US IncMyrbetriq$135$35,64475 claims
AbbVieVraylar, Linzess$2,333$26,70230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Carmel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →